ENETS Abstract Search

Peptide Receptor Radionuclide Therapy (PRRNT) in Patients with Metastasized Neuroendocrine Tumor Having Single or Non-functional Kidney - Is it Safe?

#238

Introduction: Nephrotoxicity is one of the primary concerns in PRRNT of metastasized neuroendocrine tumors (NET).

Aim(s): To determine if PRRNT can be performed in patients (pts) with only one kidney or non-functional kidney(s) and progressive, life-threatening NET.

Materials and methods: Twenty-five patients (mean age 57 yr±13) with metastasized NET and having a single kidney (n=19), functional single kidney (n=4), or on dialysis (n=2) were treated with Y-90 (n=2) , Lu-177 (n=21) DOTATATE and combination of Lu-177 and Y-90 (n=2) under renal protection using amino acids (lysine+arginine) and in addition a gelatine agent (Gelofusal).

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Prasad V, Hoersch D, Zachert C, Baum R,

Keywords: single kidney, non-functional kidney, peptide receptor radionuclide therapy, NET,

To read the full abstract, please log into your ENETS Member account.